CPC C07K 5/06078 (2013.01) [A61K 38/005 (2013.01); A61K 38/05 (2013.01); A61K 45/06 (2013.01); C07D 205/08 (2013.01); C07D 207/26 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01); C07D 401/12 (2013.01); C07K 5/06191 (2013.01)] | 3 Claims |
1. A method of treating myelodysplastic syndrome (MDS) characterized by having an IDH1 mutation in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (S)—N—((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide:
or a pharmaceutically acceptable salt or hydrate thereof.
|